

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 November 2002 (28.11.2002)

PCT

(10) International Publication Number
WO 02/094322 A2

(51) International Patent Classification⁷: **A61K 45/06**

(74) Agent: **THALSØ-MADSEN, Birgit**; LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup (DK).

(21) International Application Number: PCT/DK02/00351

(22) International Filing Date: 24 May 2002 (24.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/292,928 24 May 2001 (24.05.2001) US

(71) Applicant (for all designated States except US): **LEO PHARMA A/S** [DK/DK]; Industriparken 55, DK-2750 Ballerup (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BINDERUP, Lise** [DK/DK]; Ludvig Hegners Allé 8A, DK-2630 Taastrup (DK). **BRAMM, Erik** [DK/DK]; Knud Anchers Vej 85, DK-2610 Rødovre (DK). **HJARNAA, Pernille-Julia, Vig** [DK/DK]; Krogen 9, DK-3060 Espergærde (DK). **HAMBERG, Karin, Jexner** [DK/DK]; Granholmen 18, DK-2840 Holte (DK).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES



[I]

(57) Abstract: Pharmaceutical composition comprising, as a first anti-neoplastic drug, cyanoguanidine IKK inhibitors, and in particular compounds of formula (I) wherein n is 0, 1 or 2; each R independently represents halogen, trifluoromethyl, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, nitro, sulfo, cyano, amino or carboxy groups; Q is a straight or branched, saturated or unsaturated C₄₋₂₀ divalent hydrocarbon radical; X is a bond, amino, O, S, carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocabonyloxy, oxycarbonylamino or oxythiocarbonylamino; A is di-(C₁₋₄alkoxy)phosphinyloxy, C₁₋₄alkoxycarbonyl,

C₁₋₄alkoxycarbonylamino, C₃₋₁₂ carbocyclic ring or C₃₋₁₂ heterocarbocyclic ring optionally substituted with one or more R₁; R₁ being independently selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, nitro, cyano, amino, sulfo, carboxy, carboxamido, sulfamoyl or C₁₋₄hydroxyalkyl; in combination with a second anti-neoplastic drug are provided.

WO 02/094322 A2

Combination medicament for treatment of neoplastic diseases

FIELD OF INVENTION

5 The invention relates to pharmaceutical combination compositions effective in the treatment of neoplastic diseases, to the preparation of said compositions, and to methods of using said combination compositions.

BACKGROUND OF THE INVENTION

10 Neoplastic diseases are characterised by autonomous growth of cells. Neoplastic diseases may be benign, i.e. the growth is contained and does not spread to other organs or parts of the body. Neoplastic diseases may also be malignant where the growth spreads to other organs or parts of the body by infiltration or metastases. Malignant neoplastic diseases are also known as cancer.

15 Patients with neoplastic diseases are conveniently treated by surgery, ionising radiation, medication, or a combination thereof. Several types of medicaments or drugs for the treatment of neoplastic diseases are known, and one way of classifying these medicaments is suggested in Abeloff *et al* (Eds.), Clinical Oncology, Churchill
20 Livingston Inc., New York, 1995 . Medicaments for treatment of neoplastic diseases (anti-neoplastic drugs) may conveniently be classified as chemotherapeutic agents, hormonal agents or biological response modifiers.

Chemotherapeutic agents may be further classified according to the mechanism
25 whereby they effect their response e.g. as S-triazine derivatives such as altretamine; as enzymes such as asparaginase; as antibiotic agents such as bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitomycin and plicamycin; alkylating agents such as busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamid, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan,
30 procarbazine and thiotepa; as antimetabolites such as cladribine, cytarabine, floxuridine, fludarabine, fluoruracil, hydroxyurea, mercaptopurine, methotrexate, pentostatin and thioguanine; and as antimitotic agents such as etoposide, paclitaxel, teniposide, vinblastine and vincristine.

Hormonal agents may be further classified according to the mechanism whereby they effect their response, e.g. as aromatase inhibitors such as aminoglutethimide; as antiestrogens such as tamoxifen, formestan and letrozol; and as antiandrogen such as flutamide.

5

Biological response modifiers may be further classified according to the mechanism whereby they effect their response, e.g. as lymphokines such as aldesleukin; as interferon such as interferon- α ; and as growth factors such as erythropoietin, filgrastim and sagramostim.

10

A number of medicaments do not fall naturally within these classifications. Examples of such medicaments are differentiating agents such as all-trans retinoic acid, immunoregulators such as levamisole, and vitamin D analogues, such as seocalcitol.

15

Other types of medicaments based on e.g monoclonal antibodies, tumour necrosis factor, gene therapy and angiogenesis inhibitors have been suggested for treatment of neoplastic diseases, but they are still in the exploratory phase.

20

Despite the classification indicated above, many anti-neoplastic drugs and ionising radiation seem to rely on a common principal mechanism, namely apoptosis, by which they effect their responses. Apparently, the direct effect of anti-neoplastic drugs and ionising radiation may be of less importance to the final results of the therapy than their ability to induce apoptosis in the cells. [Friesen, Nature Medicine, 2, 574-577, 1996; Fisher, Cell, 78, 539-542, 1994]. Apoptosis is a genetically

25

encoded cell death programme characterised by an "active decision" by the cell based on information from its environment, its own internal metabolism, its developmental history, etc to die. Unlike cells undergoing necrosis, cells stimulated to enter apoptosis are often capable of survival, but opt to die for the good of the whole organism. Apoptosis is also different from necrosis in that necrosis is often associated with traumatised tissue and cell bursts, whereas the cells condense in the course of apoptosis, and are degraded intracellularly in a controlled manner [Tran, Science and Medicine, 6, 18-27, 1999; Williams, Trends Cell Biol., 2, 263-267, 1992].

30

Unfortunately, neoplastic cells are very effective in developing biochemical mechanisms that allow cellular resistance to medicaments or ionising radiation. In fact, resistance is a common clinical problem in the therapy of neoplastic diseases [Cun-Yu Wang, Nature Medicine, 5, 412-417, 1999]. In order to overcome this

5 resistance, therapy generally involves more than one medicament or combinations of ionising radiation and medicaments. Several types of resistance are known, e.g. enhanced drug metabolism, altered drug accumulation, drug target amplification and repair of damaged targets. Resistance to apoptosis is another type of multi-drug resistance, that likely explains a significant proportion of treatment failures [Fisher,

10 Cell, 78, 539-542, 1994]. For convenience, the terms "medicament" and "drug" are used interchangeably, and are intended to indicate the same.

At the cellular level it is well recognised that Nuclear Factor κ B (NF κ B) plays a pivotal role in apoptosis and resistance to apoptosis. It is also described that an NF κ B

15 inhibitor, I κ B, and an I κ B kinase complex, IKK, control the level of activated NF κ B [Levkau, 1, 227-233, 1999; Wang, Science, 274, 784-787, 1996; Madrid, Molecular and Cellular Biology, 5, 1626-1638, 2000]. Accordingly, the NF κ B-I κ B-IKK system has been suggested as a target in the treatment of neoplastic diseases.

20 Cusack, Cancer Research, 60, 2323-2330, 2000 and Wang, Nature Medicine 5, 412-417, 1999 teach that a particular chemotherapeutic agent, namely the topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) activates NF κ B activity in cells to induce resistance toward itself, and that an adenoviral transfer of an I κ B, I κ B α , to inhibit

25 NF κ B promotes chemosensitivity to treatment with CPT-11.

WO98/37228 teaches that an agent which decreases IKK activity or that alters the association of IKK and I κ B can be useful for allowing apoptosis to occur in a tumour cell by increasing the level of unphosphorylated I κ B, which can bind to NF κ B and


30 decrease the level of active NF κ B in the tumour cell.

Rossi, Nature, 403, 103-108, 2000 teaches that cyclopentenone prostaglandins inhibit I κ B kinase, and that this makes cyclopentenone prostaglandins potentially valuable in the treatment of cancers, inflammation and viral infections.

35

SUMMARY OF THE INVENTION

- 5 It has surprisingly been found that certain cyanoguanidine compounds are capable of modulating the level of activated NF κ B through inhibition of the I κ B kinase complex (abbreviated IKK in the following), thereby preventing resistance to the apoptosis effected by other anti-neoplastic drugs and ionising radiation. Cyanoguanidine compounds are thus able to increase the effect of other anti-neoplastic treatments.
- 10 Synergistic effects may therefore be obtained in the treatment of patients with neoplastic diseases by combining treatment with cyanoguanidine compounds with other types of anti-neoplastic treatment, e.g. treatment with chemotherapeutic agents, hormonal agents, biological response modifiers, angiogenesis inhibitors, differentiating agents and ionising radiation.
- 15 It is a well-recognised problem with all anti-neoplastic therapies that they give rise to severe adverse effects such as nausea, hair loss, myelosuppression etc because of their toxicity. Due to the seriousness of the prognosis for neoplastic diseases, a high level of adverse effects can be accepted if the therapy appears curative. However,
- 20 synergistically increasing the effect of traditional anti-neoplastic treatments by concomitantly administering cyanoguanidine compounds to patients, may allow for a reduction of the doses thus providing more effective and less toxic treatments with fewer adverse effects.
- 25 Accordingly, in one aspect the invention relates to a pharmaceutical composition comprising a compound of the general formula I



wherein

n is 0, 1 or 2;

each R independently represents halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, sulfo or carboxy groups;

Q is a straight or branched, saturated or unsaturated C₄₋₂₀ divalent hydrocarbon radical;

X is a bond, amino, O, S, carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocabonyloxy, oxycarbonylamino or oxythiocarbonylamino;

A is di-(C₁₋₄ alkoxy)phospinoxyloxy, C₁₋₄ alkoxy carbonyl, C₁₋₄ alkoxy carbonylamino, C₃₋₁₂ carbocyclic ring or C₃₋₁₂ heterocarbocyclic ring optionally substituted with one or more R₁; R₁ being independently selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, carboxy, sulfo, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl; or a pharmaceutical acceptable salt or N-oxide thereof in combination with a second anti-neoplastic drug together with a pharmaceutically acceptable excipient.

In a further aspect, the invention relates to a pharmaceutical combination composition comprising in separate containers and intended for simultaneous or sequential administration a compound of the general formula I in combination with a second anti-neoplastic drug together a pharmaceutically acceptable excipient or vehicle.

In a still further aspect, the invention relates to (a) a container comprising a unit dosage of a compound of the general formula I together with a pharmaceutical acceptable excipient or vehicle and (b) a container comprising a unit dosage of a second anti-neoplastic drug together with a pharmaceutically acceptable excipient or vehicle.

In a still further aspect, the invention relates to a pharmaceutical composition comprising as a first compound a cyanoguanidine IKK inhibitor in combination with an anti-neoplastic drug together with a pharmaceutically acceptable excipient or vehicle.

In a still further aspect, the invention relates to a pharmaceutical combination composition comprising in separate containers and intended for simultaneous or

sequential administration a cyanoguanidine IKK inhibitor in combination with an anti-neoplastic drug together with a pharmaceutically acceptable excipient or vehicle.

5 In a still further aspect, the invention relates to (a) a container comprising a unit dosage of a cyanoguanidine IKK inhibitor together with a pharmaceutically acceptable excipient or vehicle and (b) a container comprising a unit dosage of a second anti-neoplastic drug together with a pharmaceutically acceptable excipient or vehicle.

10

In a still further aspect, the invention relates to a method of treating a neoplastic disease comprising administering to a patient in need thereof an effective amount of a compound of the general formula I and simultaneously or sequentially therewith administering an effective amount of a second anti-neoplastic drug and/or an

15 effective dosage of ionising radiation.

20

In a still further aspect, the invention relates to a method of treating a neoplastic disease comprising administering to a patient in need thereof an effective amount of a cyanoguanidine IKK inhibitor and simultaneously or sequentially therewith administering an effective amount of a second anti-neoplastic drug and/or and effective dosage of ionising radiation.

25

In a still further aspect, the invention provides a means of inhibiting proliferation of cancer cells in a host comprising administering to said host a combination of an effective amount of a cyanoguanidine IKK inhibitor, e.g. a compound of formula I and an effective amount of another anti-neoplastic drug or ionising radiation.

30

In a still further aspect, the invention relates to the use of a compound of the general formula I in combination with second anti-neoplastic drug for the preparation of a medicament for the treatment of neoplastic diseases, intended for simultaneous or sequential administration with the compound of formula I.

In a still further aspect, the invention relates to the use of a cyanoguanidine IKK inhibitor in combination with a second anti-neoplastic drug for the preparation of a

medicament for the treatment of a neoplastic disease intended for simultaneous or sequential administration with said cyanoguanidine IKK inhibitor.

5

DETAILED DESCRIPTION OF THE INVENTION

In the present context, the term "vitamin D analogue" is intended to indicate a synthetic compound comprising a vitamin D scaffold with side chain modifications and/or modifications of the scaffold itself. The term is not intended to include naturally occurring vitamin D derivatives such as metabolites.

The term "alkyl" is intended to indicate a univalent radical derived from straight, branched or cyclic alkane by removing a hydrogen atom from any carbon atom. The term includes the subclasses primary, secondary and tertiary alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert.-butyl, isopentyl and isohexyl.

The term "divalent hydrocarbon radical" is intended to include straight or branched, saturated or unsaturated carbon chains, e.g. alkylene, alkenylene or alkynylene.

20

The term "alkoxy" is intended to indicate a radical of formula OR', wherein R' is alkyl as defined above, e.g. methoxy, ethoxy, propoxy, butoxy, etc.

The term "alkoxycarbonyl" is intended to indicate a radical of formula -COOR' wherein R' is alkyl as defined above, e.g. methoxycarbonyl, ethoxycabonyl, n-propoxycarbonyl, isopropoxycarbonyl, etc.

The term "carbocyclic ring" is intended to include radicals of saturated or unsaturated rings, optionally fused bicyclic rings, e.g. cyclopropyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, dihydronaphthyl, pentalenyl, indanyl and indenyl.

The term "hetero carbocyclic ring" is intended to include radicals of saturated or unsaturated heterocyclic rings, optionally fused bicyclic rings, with one or more heteroatoms selected from O, S and N, e.g. pyridyl, tetrazolyl, thiazolyl, imidazolyl,

35

pyrazolyl, oxazolyl, isoxazolyl, thienyl, pyrazinyl, pyranyl, isothiazolyl, benzimidazolyl and benzofuranyl, pyrrolyl, furanyl, pyrazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, tetrahydrothieyl, tetrahydrofuranyl, tetrahydropyranyl, piperidyl, quinolyl, isoquinolyl, 1,2-dihydroquinolyl, etc.

5

The term "halogen" is intended to indicate fluoro, chloro, bromo or iodo.

The term "pharmaceutically acceptable salt" is intended to indicate salts prepared by reacting a compound of formula I comprising a basic group with a suitable inorganic or organic acid, e.g. hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric, acetic, phosphoric, lactic, maleic, phthalic, citric, propionic, benzoic, glutaric, gluconic, methanesulfonic, salicylic, succinic, tartaric, toluenesulfonic, sulfamic or fumaric acid. Pharmaceutically acceptable salts of compounds of formula I comprising an acidic group may be prepared by reaction with a suitable base such as sodium hydroxide, potassium hydroxide, ammonia or the like.

10
15

The term "N-oxide" is intended to indicate e.g. pyridyl N-oxide derivatives of the compounds of the invention. Such compounds may be prepared by oxidation of the pyridyl N by a suitable oxidising agent, e.g. 3-chloro-perbenzoic acid in an inert solvent, e.g. dichloromethan.

20

The term "resistance" is intended to indicate a reduced sensitivity to a given treatment. Sensitivity can be defined in terms of IC_{50} , which indicates the amount or concentration of a given treatment or ionising radiation, which is lethal to 50% of the cells. An increase in IC_{50} signifies a reduced sensitivity to a given therapy, and the cells are termed "resistant" if IC_{50} increases by a factor of 10 or more, e.g. by a factor of 20-50. This definition is of particular relevance for in vitro studies, but of less relevance for in vivo studies, not to mention treatment of human beings. For in vivo studies and in human therapy a more feasible definition of resistance may be expressed as the overall failure of treatment, defined as progressing neoplastic diseases in a patient who previously responded to treatment. Progressing neoplastic diseases may be defined as $\geq 25\%$ increase in the size of one or more lesions or the appearance of new lesions [WHO Handbook for reporting results of cancer treatment, Publication No.48, Geneva, WHO, 1979].

30
35

The term "modulate" when used in relation to levels of activated NFκB means that the level of activated NFκB is increased or decreased compared to the level present in the absence of a compound of the general formula I. The level of activated NFκB is preferably decreased by the compound of formula I.

5


The term "effective amount" is intended to indicate the amount which is required to confer a therapeutic effect to the treated patient, and is typically determined on the basis of the age, surface area, body weight, the desired effect, and condition of the patient.

10

The term "excipient" when used herein is intended to indicate all substances in a pharmaceutical formulation which are not active ingredients, such as e.g. carriers, binders, lubricants, thickeners, surface active agents, preservatives, emulsifiers, buffers, flavouring agents or colourants.

15

The term "cyanoguanidine compound" is intended to indicate a compound comprising the structure shown in formula II



20

The term comprises, but is not limited to compounds of formula I, e.g. cyanoguanidine compounds disclosed in WO 00/61559, WO 00/61561, WO 00/76516, WO 00/76517 and PCTDK01/00750 are also included in this definition.

25

Preferred compounds of formula I are those wherein A is a phenyl, optionally substituted with a substituent selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxycarbonyl, nitro, cyano, amino, carboxy, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl.

30

In another preferred embodiment of the invention A is an optionally substituted tetrahydropyranyl.

In a further preferred embodiment of the invention X is O.

In a further preferred embodiment of the invention X is amino.

- 5 In a still further preferred embodiment of the invention Q is a C₄₋₁₂ divalent hydrocarbon radical.

In a still further preferred embodiment of the invention n is 0 or n is 1, R being C₁₋₄ alkoxy.

10

In a still further preferred embodiment of the invention the compound of formula I is selected from the group consisting of

N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine

N-cyano-N'-(7-phenoxyheptyl)-N''-(4-pyridyl) guanidine

- 15 N-(12-(*tert*-butoxycarbonylamino)dodecanyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-cyano-N'-(11-(tetrahydropyran-2-yloxy)-undecanyl)-N''-(4-pyridyl) guanidine

N-cyano-N'-(6-(2-methoxyphenoxy)hexyl)-N''-(4-pyridyl) guanidine

N-(6-(2,4,5-trichlorophenoxy)hexyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-(6-(1-chlorophenoxy)hexyl))-N'-cyano-N''-(4-pyridyl) guanidine

20

Compounds of the general formula I contain asymmetric carbon atoms as well as carbon-carbon double bonds, which allow for isomeric forms. It is understood that the present invention relates to any tautomer, diastereomer and optical isomer expressed by the general formula I, either in pure form or as mixtures thereof.

25

Compounds of formula I are known from the literature and methods of their synthesis have previously been disclosed [EP660 823, WO 98/54141, WO 98/54143 and WO 98/54145]. While the compounds have been suggested for cancer therapy, no indication in these publications has been offered as to the mechanisms of action to which they owe their effect nor to any synergistic effect between cyanoguanidine compounds and other types of treatment for neoplastic diseases.

30

NFκB is a member of the Rel family of transcription factors, which are ubiquitous in animal cells. Rel proteins can form dimers, the most common of which is designated NFκB. NFκB is a p50/p65 heterodimer which can activate transcription of genes

35

containing the appropriate κ B binding site. In non-stimulated cells, NF κ B is maintained in the cytoplasm by an interaction with NF κ B inhibiting proteins, the I κ Bs. In response to cell stimulation by e.g. anti-neoplastic drugs or ionising radiation an I κ B kinase complex (IKK) is rapidly activated and phosphorylates two serine residues in the NF κ B binding domain of I κ B. The phosphorylated I κ B is then degraded by a 26S proteasome whereas NF κ B is spared from degradation and translocates into the nucleus [Wang, Science, 274, 784-787, 1996, Cusak, Cancer Research, 60, 2323-2330, 2000; Karin, Immunology, 12, 2000, 85-98]. NF κ B is thus always present in the cell, but in an inactivated form in non-stimulated cells. After translocation into the nucleus NF κ B induces inter alia the anti-apoptotic genes c-IAP1, c-IAP2, TRAF1, TRAF2, Bfl-1/A1, Bcl-X_L and Mn-SOD [Platel, Oncogene, 19, 2000, 4159-4169], which bring about resistance in the cells to apoptosis. This effect is referred to as the anti-apoptotic effect of NF κ B, and the effect may be quantified by measuring the expression of compounds encoded by any of said genes, by any suitable means known in the art, in the presence and absence of compounds modulating the level of activated NF κ B. Any compound capable of reducing the transcription of said genes to a level less than 50%, e.g. less than 30%, such as less than 20% of the level in the absence of said compound is said to reduce the antiapoptotic effect of NF κ B. Anti-neoplastic drugs and ionising radiation thus induce resistance in the cells to the treatments, which render them ineffective. Accordingly, activated NF κ B is a key factor in induced resistance in e.g. cancer cells to anti-neoplastic drugs and/or to ionising radiation. This is further supported by the fact that constitutively activated NF κ B is found in cells from resistant cancer tumours [Patel, Oncogene, 19, 4159-4169, 2000].

In cells not exhibiting resistance to anti-neoplastic treatments, a reduction of the level of activated NF κ B in the cell, e.g. by controlling the activity of IKK, will reduce the expression levels of genes encoding for anti-apoptotic factors inducing apoptosis in the cells [Schwartz, Surgical Oncology.8, 1999, 143-153].

Accordingly, a reduction of the level of activated NF κ B, e.g. by cyanoguanidine effected IKK inhibition, has therapeutic value in the treatment of neoplastic diseases at at least two levels. Firstly, treatment with cyanoguanide compounds will induce apoptosis in the cells so that cyanoguanidine compounds themselves may effect death of neoplastic cells. Secondly, it will increase the effect of other anti-neoplastic

treatments by preventing the resistance to the treatment normally induced by these treatments.

I κ B is non-covalently bound to NF κ B and masks its nuclear localisation signal, thereby preventing translocation into the nucleus. Various I κ B have been identified and e.g. I κ B α and I κ B β are expressed in most cells where they bind to p65 Rel proteins, i.e. NF κ B. Different I κ B are phosphorylated by different factors allowing activation of NF κ B in response to different stimuli.

- 5
- 10 The I κ B kinase complex consist of three subunits, namely IKK α , IKK β and IKK γ , with a combined molecular weight of 900 kDa. IKK α and IKK β both exhibit I κ B kinase activity and phosphorylate I κ B, whereas IKK γ is a regulatory subunit. IKK α is 85 kDa protein and IKK β is a 87 kDa protein, and the two subunits show a large degree of homology. Whereas both IKK α and IKK β are catalytically active, it has surprisingly
- 15 been shown that only IKK β is essential for IKK phosphorylation of I κ B.

- The term "inhibitor" when used herein is intended to indicate a compound capable of decreasing or even blocking the activity of a given enzyme system, e.g. IKK, towards a given substrate. Several methods to identify compounds capable of inhibiting IKK
- 20 are known to the person skilled in the art. Such a method may make the form of an assay which may comprise e.g. isolated IKK or subunits thereof exposed to compounds suspected to modulate the IKK activity. Methods of obtaining isolated IKK or subunits thereof are known in the art. They comprise e.g. immunoprecipitation or expression of IKK or subunits thereof in a suitably selected
- 25 host cell, e.g. as disclosed in WO98/37228. The IKK activity may conveniently be measured by determining phosphorylation of e.g. I κ B, either directly or by using antibodies against phosphorylated I κ B. Other suitable substrates for IKK may also be used. The result from such an experiment conducted in the presence of a given compound is compared to a similar experiment conducted in the absence of said
- 30 compound. The assay may also be a cellular assay in which cells expressing IKK or subunits thereof are exposed to compounds suspected of modulating IKK activity. The cells in a cellular assay may be manipulated to enhance the expression level of IKK or subunits thereof. Methods for manipulating the expression level of proteins in cells are known in the art examples of which are genetic manipulation, classic
- 35 mutation and selection. Following exposure for an appropriate amount of time, the

cells may be collected, lysed, and the IKK immunoprecipitated using an appropriate antibody. A substrate, I κ B or another suitable substrate may then be added to the immunocomplex, and its ability to phosphorylate the substrate may be determined as described above, and the result compared to the result from a similar experiment performed in the absence of the compound under investigation.

The ability of compounds to modulate the activity of IKK or subunits thereof in a cellular assay may also be determined without disrupting the cells through lysis. After exposure of the cells to a compound for an appropriate amount of time, the secretion from the cells of e.g. specific cytokines regulated by NF κ B may be measured. Examples of such specific cytokines are tumour necrosis factor α (TNF α) and interleukin 1 (IL1). The result is compared to results from similar experiments conducted in the absence of the compound under investigation. The specific compounds regulated by NF κ B and secreted by the cell may vary between different types of cells. A person skilled in the art are capable of choosing a relevant compound which to measure for a given cell system.

Regardless of how an IKK assay is run, a compound which reduces the activity of either IKK or the level of activated NK κ B to a level less than 50%, e.g. less than 30% or even less than 20% of the level in the absence of said compound is said to inhibit IKK.

The formulations of the present invention, both for veterinary and for human medical use, comprise active ingredients in association with a pharmaceutically acceptable carrier(s) and optionally other therapeutic ingredient(s). The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.

Examples of anti-neoplastic drugs which may suitably be included in the composition of the invention as the second active compound are chemotherapeutic agents e.g. S-triazine derivatives such as altretamine; enzymes such as asparaginase; antibiotic agents such as bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, mitomycin and plicamycin; alkylating agents such as busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamid, dacarbazine, ifosfamide, lomustine, mechlorethamine, melphalan, procarbazine and thiotepa; antimetabolites

such as cladribine, cytarabine, floxuridine, fludarabine, fluoruracil, hydroxyurea, mercaptopurine, methotrexate, pentostatin and thioguanine; and antimitotic agents such as etoposide, paclitaxel, teniposide, vinblasine and vincristine; hormonal agents e.g. aromatase inhibitors such as aminoglutethimide; antiestrogens such as
5 tamoxifen, formestane and letrozol; as antiandrogen such as flutamide; and biological response modifiers e.g. lymphokines such as aldesleukin; interferon such as interferon- α ; and growth factors such as erythropoietin, filgrastim and sargramostim, differentiating agents such as all-trans retinoic acid and vitamin D analogues, e.g. seocalcitol, and immunoregulators such as levamisole, and monoclonal antibodies,
10 tumour necrosis factor and angiogenesis inhibitors.

The formulations include e.g. those in a form suitable for oral, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular, intraperitoneal, intraarticular and intravenous), transdermal, and topical, nasal or buccal administration.

15 By the term "dosage unit" is meant a unitary, i.e. a single dose which is capable of being administered to a patient, and which may be readily handled and packed, remaining as a physically and chemically stable unit dose comprising either the active material as such or a mixture of it with solid or liquid pharmaceutical diluents
20 or carriers.

The formulations may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy, e.g. as disclosed in Remington, The Science and Practice of Pharmacy, 20th ed., 2000. All methods
25 include the step of bringing the active ingredient into association with the carrier, which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.

30 Formulations of the present invention suitable for oral administration may be in the form of discrete units as capsules, sachets, tablets or lozenges, each containing a predetermined amount of the active ingredient; in the form of a powder or granules; in the form of a solution or a suspension in an aqueous liquid or non-aqueous liquid,
35 such as ethanol or glycerol; or in the form of an oil-in-water emulsion or a

water-in-oil emulsion. Such oils may be edible oils, such as e.g. cottonseed oil, sesame oil, coconut oil or peanut oil. Suitable dispersing or suspending agents for aqueous suspensions include synthetic or natural gums such as tragacanth, alginate, acacia, dextran, sodium carboxymethylcellulose, gelatin, methylcellulose and
5 polyvinylpyrrolidon. The active ingredients may also be administered in the form of a bolus, electuary or paste.

A tablet may be made by compressing or moulding the active ingredient optionally with one or more accessory ingredients. Compressed tablets may be prepared by
10 compressing, in a suitable machine, the active ingredient(s) in a free-flowing form such as a powder or granules, optionally mixed by a binder, such as e.g. lactose, glucose, starch, gelatine, acacia gum, tragacanth gum, sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes or the like; a lubricant such as e.g. sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium
15 acetate, sodium chloride or the like; a disintegrating agent such as e.g. starch, methyl cellulose, agar, bentonite, xanthan gum or the like or dispersing agent. Moulded tablets may be made by moulding, in a suitable machine, a mixture of the powdered active ingredient and suitable carrier moistened with an inert liquid diluent.

20 Formulations for rectal administration, e.g. injection or infusion, may be in the form of a suppository incorporating the active ingredients and a carrier, or in the form of an enema.

25 Formulations suitable for parenteral administration conveniently comprise a sterile oily or aqueous preparation of the active ingredients, which is preferably isotonic with the blood of the recipient, e.g. isotonic saline, isotonic glucose solution or buffer solution. Liposomal formulations may also be used to present the active ingredients for parenteral administration. The formulation may be conveniently sterilised by for
30 instance filtration through a bacteria retaining filter, addition of sterilising agent to the formulation, irradiation of the formulation or heating of the formulation.

Alternatively, the composition of the present invention may be provided as a sterile, solid preparation, e.g. a freeze-dried powder, which is readily dissolved in a sterile
35 media just prior to use.

Transdermal formulations may be in the form of a plaster.

Formulations suitable for ophthalmic administration may be in the form of a sterile aqueous preparation of the active ingredients, which may be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems may also be used to present the active ingredient for ophthalmic administration.

Formulations suitable for topical or ophthalmic administration include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in-oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops.

In addition to the aforementioned ingredients, the formulations of a cyanoguanidine IKK inhibitor, e.g. a compound of formula I and of a second anti-neoplastic drug may include one or more additional ingredients such as diluents, buffers, flavouring agents, colourant, surface active agents, thickeners, preservatives, e.g. methyl hydroxybenzoate (including anti-oxidants), emulsifying agents and the like.

In addition to the formulations described previously, the compositions can also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation (e.g. subcutaneously or intramuscular) or by intramuscular injection. Thus, for example, the components of the present invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in a pharmaceutically acceptable oil), or ion exchange resin, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

In the systemic treatment using the present invention daily doses of from 0.001-200 mg per kilogram body weight, preferably from 0.002-50 mg/kg of mammal body weight, for example 0.003-10 mg/kg of a cyanoguanidine IKK inhibitor, e.g. a compound of formula I and a second anti-neoplastic drug are administered, typically corresponding to a daily dose for an adult human of from 0.2 to 1500 mg of each compound. In the topical treatment of dermatological disorders, ointments, creams or lotions containing from 0.1-750 mg/g, and preferably from 0.1-500 mg/g, of a

cyanoguanidine IKK inhibitor, e.g. a compound of formula I and a second anti-neoplastic drug are administered. For topical use in ophthalmology ointments, drops or gels containing from 0.1-750 mg/g, and preferably from 0.1-500 mg/g, of a cyanoguanidine IKK inhibitor, e.g. a compound of formula I and a second anti-

5 neoplastic drug are administered. The oral compositions are formulated, preferably as tablets, capsules, or drops, containing from 0.05-250 mg, preferably from 0.1-125 mg, of a cyanoguanidine IKK inhibitor, e.g. a compound of formula I and a second anti-neoplastic drug per dosage unit.

10 In a further aspect, the invention relates to a non-simultaneous administration of a cyanoguanidine IKK inhibitor, e.g. a compound of formula I and of a second anti-neoplastic drug and/or the application of ionising radiation to a patient. The interval between dosing of the individual compounds and/or ionising radiation as well as the dosing frequency of the individual compounds and/or ionising radiation constituting a
15 combination treatment is determined by many factors including, but not limited to the severity of the disease to be treated, the general condition of the patient, the desired effect and the progress of the treatment. It is within the capability of a skilled physician or veterinary to determine the interval between the individual dosages as well as the dosage frequency, in order to utilise the present invention to
20 its fullest extent.

The neoplastic disease to be treated with a combination of a cyanoguanidine IKK inhibitor, e.g. a compound of formula I and a second anti-neoplastic drug and/or the application of ionising radiation is preferably a malignant disease, i.e. cancer. The
25 cancer disease may e.g. be hematological cancer, such as leukaemia, acute myeloideleukaemia, chronic myeloide leukaemia, chronic lymphatic leukaemia, myelodysplasia, multiple myeloma, Hodgkin's disease or non-Hodgkin's lymphoma or solid tumour cancer, such as fibrosarcom, small or non-small cell lung carcinoma, gastric, intestinal or colorectal cancer, prostate, ovarian or breast cancer, brain, head
30 or neck cancer, cancer in the urinary tract, such as kidney or bladder cancer, malignant melanoma, liver cancer, uterine or pancreatic cancer, etc.

In a preferred embodiment, these cancers are resistant to conventional treatment of neoplastic diseases such as chemotherapeutic agents, hormonal agents and
35 biological response modifiers, as indicated above, and/or to ionising radiation.

The invention is further illustrated by the following, non-limiting example.

EXAMPLES

- 5 Experiments were conducted in nude mice inoculated with cancer cells to assess the efficacy of combination therapy using compounds of formula I, *in casu* N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''(4-pyridyl)guanidine (hereafter Compound A) and various anti-neoplastic drugs.
- 10 Compound A was prepared as disclosed in *e.g.* EP660 823, WO 94/06770, WO 98/54141 and WO 98/54143.

The following anti-neoplastic drugs were employed in the experiments

- 15 • Etoposide is a well-known generic anti-neoplastic drug belonging to the group of antimitotic drugs. Etoposide has significant antitumour activity against *inter alia* germ-cell malignancies, lung cancer, non-Hodgkin's lymphomas, leukemias, Kaposi's sarcoma, neuroblastoma and soft-tissue sarcomas. Vepesid®, available from Bristol-Meyers Squibb, was used as an example of etoposide.
- 20 • TNP-470 is an experimental drug from Takeda. It is a fumagilin analogue, and it is believed to exert its effect by inhibiting angiogenesis.
- Cyclophosphamide is a well-known generic anti-neoplastic drug belonging to the group of alkylating agents. It is a broad spectered chemotherapeutic agent administered *e.g.* to patient with lung cancer. Sendoxan® available from Asta Medica was used as an example of cyclophosphamide
- 25 • Cisplatin is a well-known generic anti-neoplastic drug belonging to the group of alkylating agents. It is a broad spectered chemotherapeutic agent administered *e.g.* to patients with lung cancer, ovarian cancer and testicle cancer. Platinol® available from Bristol Meyers-Squibbs was used as an example of cisplatin.
- 30 • Paclitaxel is a well-known generic anti-neoplastic drug belonging to the group of antimitotic agents. It is a broad spectered chemotherapeutic agent administered *e.g.* to patient with ovarian cancer and non-small cell lung carcinoma cancer. Taxol available from Bristol Meyers-Squibbs was used as an example of paclitaxel.
- 35 • Seocalcitol is an experimental drug from LEO Pharma. It is a vitamin D analogue, and it is currently in development as a drug to treat liver cancer.

The following conditions were common to all experiments

The experiments were conducted with NMRI nu/nu female mice (M&B, Ry, Denmark) kept under semi-sterile conditions. The mice were 6 weeks old on arrival, and they were allowed to acclimatise for approximately 3 weeks before the experiments were initiated. The bedding was autoclaved at 121°C for 20 minutes, the food was sterilised by irradiation, and the drinking water was filtered through a 0.2 µm filter. All handling of the mice was done in laminar flow benches.

Before use, all cell cultures were tested negative for mycoplasma infections.

Each experiment employed 40-60 mice which were inoculated in both flanks and left for the tumours to develop. Following that, the mice were divided into groups, each containing 10 mice and thus 18-20 tumors, according to the size of the tumour, *i.e.* large, medium or small. Subsequently, the mice were randomised into the groups shown in Table 1. Unless stated otherwise all doses have been given daily.

Tabel 1 Dosing regimes

Group	Dosing regime
1	Control
2	Anti-neoplastic drug
3	Compound A
4	Anti-neoplastic drug + after 1 hour compound A

The tumours were measured using digital callipers before treatment start (=baseline), twice weekly for the duration of the study, and at the end of the study. Tumour area (A) was calculated as the product of the two measured perpendicular diameters; $A = d_1 \times d_2$. For mice with only one tumour, the area of this tumour was calculated and used in the statistical analysis. For mice with two tumours, the average of the two tumour areas was calculated and used in the statistical analysis.

For each animal, an individual curve of the tumour areas observed during the study was plotted against time. The trend was an increasing growth rate of the tumours. In order to ensure an approximate linear correspondence between tumour data and time, the observations were transformed by taking the square root of the tumour areas, corresponding to tumour size in one dimension. As a summary measure of the repeated measurements of tumour areas during the study (tumour growth rate), the estimated slope of the individual curves of the square root transformed curves was used [Matthews, Br. Med. J., 300, 230-235, 1990]. The slope should be interpreted as a measure of the tumour growth rate and was estimated using linear regression analysis by time on the observations during the study. Within each group, the mean of the tumour growth rate was calculated.

Example 1

Tumour type: NYH

- 15 The NYH cell line originates from a patient with small cell lung cancer. The cell line was obtained from Rigshospitalet, Copenhagen, Denmark.
- The mice were inoculated with 1×10^7 NYH cells in 0.2 ml in each flank, and the tumours were left to grow for approximately 4 days. The duration of the dosing was 14 days. The results from the different dosing regimes are tabulated in Table 2.

Tabel 2

Dosing regime	Mean increment/day (mm/day)
Etoposide 10 mg/kg p.o.	0.41
Compound A 15 mg/kg p.o.	0.34
Combination etoposide + compound A	-0.34
Control	0.67
Cyclophosphamide 7 mg/kg p.o.	0.40
Compound A 15 mg/kg p.o.	0.26
Combination cyclophosphamide + compound A	-0.04
Control	0.61
Cisplatin 5 mg/kg i.p., once weekly	0.32
Compound A 15 mg/kg p.o.	0.02
Combination cisplatin + compound A	-0.16
Control	0.90

5 Example 2

Tumour type: HT 1080.

The HT 1080 cell line originates from a patient with human fibrosarcoma, and it was obtained from ATCC.

- 10 The mice were inoculated with 2×10^6 HT 1080 cells in 0.2 ml in each flank, and the tumours were left to grow for approximately 4 days. The duration of the dosing was 14 days. The results from the different dosing regimes are tabulated in Table 3.

Tabel 3

Dosing regime	Mean increment/day (mm/day)
Paclitaxel 1 mg/kg s.c.	0.39
Paclitaxel 2 mg/kg s.c.	0.15
Compound A 50 mg/kg p.o.	0.30
Combination paclitaxel 1 mg/kg + compound A	0.14
Combination paclitaxel 2 mg/kg + compound A	0.04
Control	0.67
Etoposide 10 mg/kg p.o.	-0.01
Compound A 50 mg/kg p.o.	0.21
Combination etoposide + compound A	-0.12
Control	0.45
TNP-470 9 mg/kg s.c.	0.51
Compound A 50 mg/kg p.o.	0.14
Combination TNP-470 + compound A	-0.10
Control	0.73
Seocalcitol 2 µg/kg p.o.	0.95
Compound A 50 mg/kg p.o.	0.24
Combination seocalcitol + compound A	0.10
Control	0.98

Example 3

5 Tumour type: Colo 320 DM

The Colo 320 DM cell line originates from a patient with human colon cancer, and it was obtained from ATCC

10 The mice were inoculated with 5×10^6 Colo 320 DM cells in 0.2 ml in each flank, and the tumours were left to grow for approximately 7 days. The duration of the dosing was 21 days. The results from the different dosing regimes are tabulated in Table 4.

Tabel 4


Dosing regime	Mean increment/day (mm/day)
TNP-470 9 mg/kg s.c.	0.29
Compound A 50 mg/kg p.o.	0.22
Combination TNP-470 + compound A	-0.07
Control	0.55

As evidenced by the results reported in Tables 2-4, there is a beneficial effect obtained by combining known anti-neoplastic drugs with compounds of formula I, *in casu* N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''(4-pyridyl)guanidine. Individual dosing of the two medicaments results in a slower development of the tumour compared to the control. The combination of the two medicaments, however, results in a much slower and in most cases, in fact, an actual decrease in the tumour size, as demonstrated by the negative value of the growth rate. The effect of the combination of anti-neoplastic drugs and compounds of formula I is thus greater than expected from the additive effect of the individual medicaments, i.e. synergistic. The synergistic effect has been demonstrated for a variety of anti-neoplastic drugs and tumour types.

CLAIMS

1. A pharmaceutical composition comprising, as a first anti-neoplastic drug, a compound of the general formula I

5



n is 0, 1 or 2;

each R independently represents halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, sulfo or carboxy groups;


10 Q is a straight or branched, saturated or unsaturated C₄₋₂₀ divalent hydrocarbon radical;

X is a bond, amino, O, S, carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocarbonyloxy, oxycarbonylamino or oxythiocarbonylamino;

15 A is di-(C₁₋₄ alkoxy)phosphinoyloxy, C₁₋₄ alkoxy carbonyl, C₁₋₄ alkoxy carbonylamino, C₃₋₁₂ carbocyclic ring or C₃₋₁₂ heterocarbocyclic ring optionally substituted with one or more R₁; R₁ being independently selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, carboxy, sulfo, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl;

20 or a pharmaceutical acceptable salt or N-oxide thereof in combination with a second anti-neoplastic drug together with a pharmaceutically acceptable excipient.

2. A pharmaceutical combination composition comprising in separate containers and intended for simultaneous or sequential administration a compound of the general
25 formula I



wherein

n is 0, 1 or 2;

each R independently represents halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, sulfo, amino or carboxy groups;

5 Q is a straight or branched, saturated or unsaturated C₄₋₂₀ divalent hydrocarbon radical;


X is a bond, amino, O, S, carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocarbonyloxy, oxycarbonylamino or oxythiocarbonylamino;

10 A is di-(C₁₋₄ alkoxy)phosphinoyloxy, C₁₋₄ alkoxy carbonyl, C₁₋₄ alkoxy carbonylamino, C₃₋₁₂ carbocyclic ring or C₃₋₁₂ heterocarbocyclic ring optionally substituted with one or more R₁; R₁ being independently selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, carboxy, sulfo, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl;

15 or a pharmaceutical acceptable salt or N-oxide thereof as a first anti-neoplastic drug in combination with a second anti-neoplastic drug together with a pharmaceutically acceptable excipient.

3. A combination composition comprising

20 (a) a container comprising, as a first anti-neoplastic drug, a unit dosage of a compound of the general formula I



25 wherein

n is 0, 1 or 2;

each R independently represents halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, sulfo or carboxy groups;

Q is a straight or branched, saturated or unsaturated C₄₋₂₀ divalent hydrocarbon radical;

X is a bond, amino, O, S, carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothi carbonyloxy, oxycarbonylamino or oxythiocarbonylamino;

A is di-(C₁₋₄ alkoxy)phosphinoyloxy, C₁₋₄ alkoxy carbonyl, C₁₋₄ alkoxy carbonylamino, C₃₋₁₂ carbocyclic ring or C₃₋₁₂ heterocarbocyclic ring optionally substituted with one or more R₁; R₁ being independently selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, carboxy, carboxamido, sulfo, sulfamoyl or C₁₋₄ hydroxyalkyl; or a pharmaceutical acceptable salt or N-oxide thereof in combination with a second anti-neoplastic drug together with a pharmaceutically acceptable excipient.

4. A composition according to any of claims 1-3 wherein R is C₁₋₄ alkyl, n being 1

5. A composition according to any of claims 1-3 wherein n = 0

6. A composition according to any claims 1-3 wherein A is a phenyl, optionally substituted with a substituent selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, carboxy, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl.

7. A composition according to any claims 1-3 wherein A is an optionally substituted tetrahydropyranyl.

8. A composition according to any of claims 1-3 wherein X is O.

9. A composition according to any claims 1-3 wherein X is amino.

10. A composition according to any of claims 1-3 wherein Q is a C₄₋₁₂ divalent hydrocarbon radical.

11. A composition according to any of claims 1-3 wherein the compound of formula I is selected from the group consisting of

N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine

N-cyano-N'-(7-phenoxyheptyl)-N''-(4-pyridyl) guanidine

5 N-(12-(*tert*-butoxycarbonylamino)dodecanyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-cyano-N'-(11-(tetrahydropyran-2-yloxy)-undecanyl)-N''-(4-pyridyl) guanidine

N-cyano-N'-(6-(2-methoxyphenoxy)hexyl)-N''-(4-pyridyl) guanidine

N-(6-(2,4,5-trichlorophenoxy)hexyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-(6-(1-chlorophenoxy)hexyl))-N'-cyano-N''-(4-pyridyl) guanidine

10

12. A composition according to any of claims 1-11, wherein the second anti-neoplastic drug is selected from the group consisting of alkylating agents, antimetabolites, antimitotic agents, antibiotic agents, hormonal agents, biological response modifiers, differentiating agents, immuno modulators, antiangiogenetic agents and vitamin D analogues.

15

13. A composition according to any of claims 1-3 wherein the compound of formula I is N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine and the anti-neoplastic drug is selected from the group consisting of alkylating agents, antimitotic agents, antiangiogenetic agents and vitamin D analogues.

20

14. A pharmaceutical composition comprising as a first antineoplastic drug, a cyanoguanidine IKK inhibitor or a pharmaceutical acceptable salt or N-oxide thereof in combination with a second anti-neoplastic drug together with a pharmaceutically acceptable excipient.

25

15. A pharmaceutical combination composition comprising in separate containers and intended for simultaneous or sequential administration a cyanoguanidine IKK inhibitor or a pharmaceutical acceptable salt or N-oxide thereof, as a first anti-neoplastic drug, in combination with a second anti-neoplastic together with a pharmaceutically acceptable excipient.

30

16. A combination composition comprising (a) a container comprising, as a first anti-neoplastic drug, a unit dosage of a cyanoguanidine IKK inhibitor or a pharmaceutically acceptable salt or N-oxide thereof together with a pharmaceutical

35

acceptable excipient or vehicle, and (b) a container comprising a unit dosage of a second anti-neoplastic drug together with a pharmaceutically acceptable excipient.

17. A composition according to any claims 14-16 wherein the cyanoguanidine IKK inhibitor is selected from the group consisting of

N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine

N-cyano-N'-(7-phenoxyheptyl)-N''-(4-pyridyl) guanidine

N-(12-(*tert*-butoxycarbonylamino)dodecanyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-cyano-N'-(11-(tetrahydropyran-2-yloxy)-undecanyl)-N''-(4-pyridyl) guanidine

10 N-cyano-N'-(6-(2-methoxyphenoxy)hexyl)-N''-(4-pyridyl) guanidine

N-(6-(2,4,5-trichloro phenoxy)hexyl)-N'-cyano-N''-(4-pyridyl) guanidine


N-(6-(1-chlorophenoxy)hexyl))-N'-cyano-N''-(4-pyridyl) guanidine

18. A composition according to any of claims 14-16, wherein the second anti-

15 neoplastic drug is selected from the group consisting of alkylating agents, antimetabolites, antimitotic agents, antibiotic agents, hormonal agents, biological response modifiers, differentiating agents, immuno modulators, antiangiogenetic agents and vitamin D analogues.

20 19. A composition according to any claims 14-16 wherein the cyanoguanidine IKK inhibitor is N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine and the second anti-neoplastic drug is selected from the group consisting of alkylating agents, antimitotic agents, antiangiogenetic agents and vitamin D analogues.

25 20. A method of treating a neoplastic disease or condition comprising administering to a patient in need thereof an effective amount of a compound of the general formula I



wherein

30 n is 0, 1 or 2;

each R independently represents halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxycarbonyl, nitro, cyano, sulfo, amino or carboxy groups;

Q is a straight or branched, saturated or unsaturated C₄₋₂₀ divalent hydrocarbon radical;

5 X is a bond, amino, O, S, carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocabonyloxy, oxycarbonylamino or oxythiocarbonylamino;

A is di-(C₁₋₄ alkoxy)phospinoxyloxy, C₁₋₄ alkoxycarbonyl, C₁₋₄ alkoxycarbonylamino, C₃₋₁₂ carbocyclic ring or C₃₋₁₂ heterocarbocyclic ring optionally substituted with one or

10 more R₁; R₁ being independently selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxycarbonyl, nitro, cyano, amino, carboxy, sulfo, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl;
or a pharmaceutical acceptable salt or N-oxide thereof as a first anti-neoplastic drug, and simultaneously or sequentially therewith administering an effective amount of a
15 second anti-neoplastic drug and/or ionising radiation.

21. A method according to claim 20 wherein R is C₁₋₄ alkyl, n being 1

22. A method according to claim 20 wherein n = 0

20

23. A method according to claim 20 wherein A is a phenyl, optionally substituted with a substituent selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxycarbonyl, nitro, cyano, amino, carboxy, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl.

25

24. A method according to claim 20 wherein A is an optionally substituted pyranlyl.

25. A method according to claim 20 wherein X is O.

30

26. A method according to claim 20 wherein X is amino.

27. A method according to claim 20 wherein Q is a C₄₋₁₂ divalent hydrocarbon radical.

35

28. A method according to claim 20 wherein the compound of formula I is selected from the group consisting of

N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine

N-cyano-N'-(7-phenoxyheptyl)-N''-(4-pyridyl) guanidine

N-(12-(*tert*-butoxycarbonylamino)dodecanyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-cyano-N'-(11-(tetrahydropyran-2-yloxy)-undecanyl)-N''-(4-pyridyl) guanidine

5 N-cyano-N'-(6-(2-methoxyphenoxy)hexyl)-N''-(4-pyridyl) guanidine

N-(6-(2,4,5-trichlorophenoxy)hexyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-(6-(1-chlorophenoxy)hexyl))-N'-cyano-N''-(4-pyridyl) guanidine

29. A method according to any of claims 20-28, wherein the second anti-neoplastic
10 drug is selected from the group consisting of alkylating agents, antimetabolites, antimitotic agents, antibiotic agents, hormonal agents, biological response modifiers, differentiating agents, immuno modulators, antiangiogenetic agents and vitamin D analogues.

15 30. A method according to claim 20 wherein the compound of formula I is N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine and the cytostatic agent is selected from the group consisting of alkylating agents, antimitotic agents, antiangiogenetic agents and vitamin D analogues.

20 31. A method according to any of claims 20-30 wherein the neoplastic disease is selected from the group consisting of hematological cancer and solid tumour cancer.

32. A method according to any claims 20-31 wherein the neoplastic disease is selected from the group consisting of leukaemia, acute myeloide leukaemia, chronic
25 myeloide leukaemia, chronic lymphatic leukaemia myelodysplasia, multiple myeloma, Hodgkin's disease or non-Hodgkin's lymphoma, fibrosarcoma, small or non-small cell lung carcinoma, gastric, intestinal or colorectal cancer, prostate, ovarian or breast cancer, head, brain or neck cancer, cancer in the urinary tract, kidney or bladder cancer, malignant melanoma, lever cancer, uterine or pancreatic cancer.

30 33. A method according to any of claims 20-32 wherein the neoplastic disease or condition exhibits resistance to treatment with anti-neoplastic drugs and/or ionising radiation.

34. A method of treating a neoplastic disease or condition comprising administering to a patient in need thereof an effective amount of a cyanoguanidine IKK inhibitor or a pharmaceutically acceptable salt or N-oxide thereof as a first anti-neoplastic drug, and simultaneously or sequentially therewith administering an effective amount of a
 5 second anti-neoplastic drug and/or ionising radiation.

35. A method according to claim 34 wherein the cyanoguanidine IKK inhibitor is selected from the group consisting of

N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine

10 N-cyano-N'-(7-phenoxyheptyl)-N''-(4-pyridyl) guanidine

N-(12-(*tert*-butoxycarbonylamino)dodecanyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-cyano-N'-(11-(tetrahydropyran-2-yloxy)-undecanyl)-N''-(4-pyridyl) guanidine

N-cyano-N'-(6-(2-methoxyphenoxy)hexyl)-N''-(4-pyridyl) guanidine

N-(6-(2,4,5-trichlorophenoxy)hexyl)-N'-cyano-N''-(4-pyridyl) guanidine

15 N-(6-(1-chlorophenoxy)hexyl))-N'-cyano-N''-(4-pyridyl) guanidine

36. A method according to any of claims 34-35, wherein the second anti-neoplastic drug is selected from the group consisting of alkylating agents, antimetabolites, antimitotic agents, antibiotic agents, hormonal agents, biological response modifiers,
 20 differentiating agents, immuno modulators, antiangiogenetic agents and vitamin D analogues.

37. A method according to claim 34 wherein the cyanoguanidine IKK inhibitor is N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine and the second anti-
 25 neoplastic drug is selected from the group consisting of alkylating agents, antimitotic agents, antiangiogenetic agents and vitamin D analogues.

38. A method according to any of claims 34-37 wherein the neoplastic disease is selected from the group consisting of hematological cancer or solid tumour cancer.


30

39. A method according to claim 37 wherein the neoplastic disease is selected from the group consisting of leukaemia, acute myeloide leukaemia, chronic myeloide leukaemia, chronic lymphatic leukaemia, myelodysplasia, multiple myeloma, Hodgkin's disease or non-Hodgkin's lymphoma, fibrosarcoma, small or non-small cell
 35 lung carcinoma, gastric, intestinal or colorectal cancer, prostate, ovarian or breast

cancer, head, brain or neck cancer, cancer in the urinary tract, kidney or bladder cancer, malignant melanoma, liver cancer, uterine or pancreatic cancer.

40. A method according to any of claims 34-39 wherein the neoplastic disease or condition exhibits resistance to treatment with anti-neoplastic drugs and/or ionising radiation

41. The use of a compound of the general formula I



10

wherein

n is 0, 1 or 2;

each R independently represents halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, sulfo, cyano, amino or carboxy groups;

- 15 Q is a straight or branched, saturated or unsaturated C₄₋₂₀ divalent hydrocarbon radical;

X is a bond, amino, O, S, carbonyl, carbonylamino, aminocarbonyl, oxycarbonyloxy, oxycarbonyl, carbonyloxy, aminocarbonyloxy, aminothiocarbonyloxy, oxycarbonylamino or oxythiocarbonylamino;

- 20 A is di-(C₁₋₄ alkoxy)phosphinoyloxy, C₁₋₄ alkoxy carbonyl, C₁₋₄ alkoxy carbonylamino, C₃₋₁₂ carbocyclic ring or C₃₋₁₂ heterocarbocyclic ring optionally substituted with one or more R₁; R₁ being independently selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, sulfo, carboxy, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl;

- 25 or a pharmaceutical acceptable salt or N-oxide thereof as a first anti-neoplastic drug, in combination with a second anti-neoplastic drug for the preparation of a medicament for the treatment of a neoplastic disease intended for simultaneously or sequential administration of said two compounds.

42. The use according to claim 41 wherein R is C₁₋₄ alkyl, n being 1.
43. The use according to claim 41 wherein n = 0.
- 5 44. The use according to claim 41 wherein A is a phenyl, optionally substituted with a substituent selected from the group consisting of halogen, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkoxy carbonyl, nitro, cyano, amino, carboxy, carboxamido, sulfamoyl or C₁₋₄ hydroxyalkyl.
- 10 45. The use according to claim 41 wherein A is an optionally substituted pyranyl.
46. The use according to claim 41 wherein X is O.
47. The use according to claim 41 wherein X is amino.
- 15 48. The use according to claim 41 wherein Q is a C₄₋₁₂ divalent hydrocarbon radical.
49. The use according to claim 41 wherein the compound of formula I is selected from the group consisting of
- 20 N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine
 N-cyano-N'-(7-phenoxyheptyl)-N''-(4-pyridyl) guanidine
 N-(12-(*tert*-butoxycarbonylamino)dodecanyl)-N'-cyano-N''-(4-pyridyl) guanidine
 N-cyano-N'-(11-(tetrahydropyran-2-yloxy)-undecanyl)-N''-(4-pyridyl) guanidine
 N-cyano-N'-(6-(2-methoxyphenoxy)hexyl)-N''-(4-pyridyl) guanidine
- 25 N-(6-(2,4,5-trichlorophenoxy)hexyl)-N'-cyano-N''-(4-pyridyl) guanidine
 N-(6-(1-chlorophenoxy)hexyl))-N'-cyano-N''-(4-pyridyl) guanidine
50. The use according to any of claims 41-49, wherein the second anti-neoplastic drug is selected from the group consisting of alkylating agents, antimetabolites,
- 30 antimitotic agents, antibiotic agents, hormonal agents, biological response modifiers, differentiating agents, immuno modulators, antiangiogenetic agents and vitamin D analogues.
51. The use according to claim 41 wherein the first anti-neoplastic drug is

N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine and the anti-neoplastic drug is selected from the group consisting of alkylating agents, antimitotic agents, antiangiogenetic agents and vitamin D analogues.

- 5 52. The use according to any of claims 41-51 wherein the neoplastic disease is selected from the group consisting of hematological cancer or solid tumour cancer.

53. The use according to claim 52 wherein the neoplastic disease is selected from the group consisting of leukaemia, acute myeloide leukaemia, chronic myeloide
10 leukaemia, chronic lymphatic leukaemia, myelodysplasia, multiple myeloma, Hodgkin's disease or non-Hodgkin's lymphoma, fibrosarcoma, small or non-small cell lung carcinoma, gastric, intestinal or colorectal cancer, prostate, ovarian or breast cancer, head, brain or neck cancer, cancer in the urinary tract, such as kidney or bladder cancer, malignant melanoma, liver cancer, uterine or pancreatic cancer.

- 15 54. The use according to any of claims 41-53 wherein the neoplastic disease or condition exhibits resistance to treatment with anti-neoplastic drugs and/or ionising radiation

- 20 55. The use of a cyanoguanidine IKK inhibitor or a pharmaceutical acceptable salt or N-oxide thereof as a first anti-neoplastic drug in combination with a second anti-neoplastic drug for the preparation of a medicament for the treatment of a neoplastic disease by simultaneously or sequential administration of said two compounds.

- 25 56. The use according to claim 55 wherein the cyanoguanidine IKK inhibitor I is selected from the group consisting of

N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine

N-cyano-N'-(7-phenoxyheptyl)-N''-(4-pyridyl) guanidine

N-(12-(*tert*-butoxycarbonylamino)dodecanyl)-N'-cyano-N''-(4-pyridyl) guanidine

- 30 N-cyano-N'-(11-(tetrahydropyran-2-yloxy)-undecanyl)-N''-(4-pyridyl) guanidine

N-cyano-N'-(6-(2-methoxyphenoxy)hexyl)-N''-(4-pyridyl) guanidine

N-(6-(2,4,5-trichlorophenoxy)hexyl)-N'-cyano-N''-(4-pyridyl) guanidine

N-(6-(1-chlorophenoxy)hexyl))-N'-cyano-N''-(4-pyridyl) guanidine

57. The use according to any of claims 55-56, wherein second anti-neoplastic drug is selected from the group consisting of alkylating agents, antimetabolites, antimitotic agents, antibiotic agents, hormonal agents, biological response modifiers, differentiating agents, immuno modulators, antiangiogenetic agents and vitamin d analogues.

58. The use according to claim 52 wherein the cyanoguanidine IKK inhibitor is N-cyano-N'-(6-(4-chlorophenoxy)hexyl)-N''-(4-pyridyl)guanidine and the anti-neoplastic drug is selected from the group consisting of alkylating agents, antimitotic agents, antiangiogenetic agents and vitamin D analogues.

59. The use according to any of claims 55-58 wherein the neoplastic disease is selected from the group consisting of hematological cancer or solid tumour cancer.

60. The use according to claim 59 wherein the neoplastic disease is selected from the group consisting of leukaemia, acute myeloid leukaemia, chronic myeloid leukaemia, chronic lymphatic leukaemia, myelodysplasia, multiple myeloma, Hodgkin's disease or non-Hodgkin's lymphoma, fibrosarcoma, small or non-small cell lung carcinoma, gastric, intestinal or colorectal cancer, prostate, ovarian or breast cancer, head, brain or neck cancer, cancer in the urinary tract, kidney or bladder cancer, malignant melanoma, liver cancer, uterine or pancreatic cancer.

61. The use according to any of claims 55-60 wherein the neoplastic disease or condition exhibits resistance to treatment with anti-neoplastic drugs and/or ionising radiation.

62. A method of inhibiting proliferation of cancer cells in a host comprising administering to said host an effective amount of a composition according to any of claims 1-19.